The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents
Abstract
BACKGROUND & AIMS Studies have produced conflicting results of the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus-associated cirrhosis treated with direct-acting antivirals (DAAs). Data from clinics are needed to accurately assess the occurrence rate of HCC in patients with cirrhosis in the real world. METHODS We collected data from a large prospective study of 2,249 consecutive patients (mean age = 65.4 years, 56.9% male) with hepatitis C virus-associated cirrhosis (90.5% with Child-Pugh class A and 9.5% with Child-Pugh class B) treated with DAAs from March 2015 through July 2016 at 22 academic and community liver centers in Sicily, Italy. HCC occurrence was evaluated by Kaplan-Meier curves. Cox regression analysis was used to identify variables associated with HCC development. RESULTS A sustained virologic response (SVR) was achieved by 2,140 patients (total = 95.2%; 95.9% with Child Pugh class A and 88.3% with Child Pugh class B; P < .001). Seventy-eight patients (3.5%) developed HCC during a mean follow-up of 14 months (range = 6-24 months). At 1 year after exposure to DAAs, HCC developed in 2.1% of patients with Child-Pugh class A with an SVR and 6.6% of patients with no SVR and in 7.8% of patients with Child-Pugh class B with an SVR and 12.4% of patients with no SVR (P < .001 by log-rank test). Albumin level below 3.5 g/dL (hazard ratio = 1.77, 95% confidence interval = 1.12-2.82, P = .015), platelet count below 120 × 109/L (hazard ratio = 3.89, 95% confidence interval = 2.11-7.15, P < .001), and absence of an SVR (hazard ratio = 3.40, 95% confidence interval = 1.89-6.12, P < .001) were independently associated increased risk for HCC. The mean interval from exposure to DAAs to an HCC diagnosis was 9.8 months (range = 2-22 months) and did not differ significantly between patients with (n = 64, 9.2 months) and without (n = 14, 12.0 months) an SVR (P = .11). A larger proportion of patients with an SVR had a single HCC lesion (78% vs 50% without an SVR; P = .009) or an HCC lesion smaller than 3 cm (58% vs 28% without an SVR; P = .07). CONCLUSIONS In an analysis of data from a large prospective study of patients with hepatitis C virus-associated compensated or decompensated cirrhosis, we found that the SVR to DAA treatment decreased the incidence of HCC over a mean follow-up of 14 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Expanding consensus in portal hypertension
de Franchis, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.022 · Cited by 3,078
EASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.014 · Cited by 2,591
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
Bruix, J., Reig, M., & Sherman, M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.041 · Cited by 1,694
van der Meer, A. J., Veldt, B. J., Feld, J. J., Wedemeyer, H., Dufour, J.-F., Lammert, F., Duarte-Rojo, A., Heathcote, E. J., Manns, M. P., Kuske, L., et al. (2012) · JAMA · doi:10.1001/jama.2012.144878 · Cited by 1,510
Panel, A. H. G. (2015) · Hepatology · doi:10.1002/hep.27950 · Cited by 1,382
EASL Recommendations on Treatment of Hepatitis C 2015
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.03.025 · Cited by 1,156
Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents
Kanwal, F., Kramer, J., Asch, S. M., Chayanupatkul, M., Cao, Y., & El-Serag, H. B. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.012 · Cited by 931
Conti, F., Buonfiglioli, F., Scuteri, A., Crespi, C., Bolondi, L., Caraceni, P., Foschi, F. G., Lenzi, M., Mazzella, G., Verucchi, G., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.06.015 · Cited by 897
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review
Falade-Nwulia, O., Suarez-Cuervo, C., Nelson, D. R., Fried, M. W., Segal, J. B., & Sulkowski, M. S. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2575 · Cited by 688
Hepatic fibrosis: concept to treatment
Trautwein, C., Friedman, S. L., Schuppan, D., & Pinzani, M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.039 · Cited by 677 · cited 1×
“Because no regimen has a proven antifibrotic effect, only drugs acting on the etiology of liver damage can stop the progression of liver fibrosis and, thus, indirectly reduce the risk of hepatic decompensation and of HCC (4).”
BackgroundCompeting risks and prognostic stages of cirrhosis: a 25‐year inception cohort study of 494 patients
D'Amico, G., Pasta, L., Morabito, A., D'Amico, M., Caltagirone, M., Malizia, G., Tinè, F., Giannuoli, G., Traina, M., Vizzini, G., et al. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12721 · Cited by 547
Self-citationNahon, P., Bourcier, V., Layese, R., Audureau, E., Cagnot, C., Marcellin, P., Guyader, D., Fontaine, H., Larrey, D., De Lédinghen, V., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.09.009 · Cited by 538
Waziry, R., Hajarizadeh, B., Grebely, J., Amin, J., Law, M., Danta, M., George, J., & Dore, G. J. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.025 · Cited by 500
Treatment of Hepatitis C: A Systematic Review
Kohli, A., Shaffer, A., Sherman, A., & Kottilil, S. (2014) · JAMA · doi:10.1001/jama.2014.7085 · Cited by 426
Simonetti, R. G., Cammà, C., Fiorello, F., Cottone, M., Rapicetta, M., Marino, L., Fiorentino, G., Craxì, A., Ciccaglione, A., Giuseppetti, R., et al. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-2-97 · Cited by 354
Self-citationBrief Communication: The Relationship of Regression of Cirrhosis to Outcome in Chronic Hepatitis C
Mallet, V., Gilgenkrantz, H., Serpaggi, J., Verkarre, V., Vallet-Pichard, A., Fontaine, H., & Pol, S. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-6-200809160-00006 · Cited by 299
Singh, S., Muir, A. J., Dieterich, D. T., & Falck-Ytter, Y. T. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.03.016 · Cited by 263
Aleman, S., Rahbin, N., Weiland, O., Davidsdottir, L., Hedenstierna, M., Rose, N., Verbaan, H., Stål, P., Carlsson, T., Norrgren, H., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit234 · Cited by 233
Backus, L. I., Belperio, P. S., Shahoumian, T. A., & Mole, L. A. (2019) · Hepatology · doi:10.1002/hep.29408 · Cited by 227
Kozbial, K., Moser, S., Schwarzer, R., Laferl, H., Al-Zoairy, R., Stauber, R., Stättermayer, A. F., Beinhardt, S., Graziadei, I., Freissmuth, C., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.06.009 · Cited by 222
Procopeț, B., & Berzigotti, A. (2017) · Gastroenterology report · doi:10.1093/gastro/gox012 · Cited by 163
Cardoso, H., Vale, A. M., Rodrigues, S., Gonçalves, R., Albuquerque, A., Pereira, P., Lopes, S., Silva, M., Andrade, P., Morais, R., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.027 · Cited by 162
Marco, V. D., Calvaruso, V., Ferraro, D., Bavetta, M. G., Cabibbo, G., Conte, E., Cammà, C., Grimaudo, S., Pipitone, R. M., Simone, F., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.036 · Cited by 147
Self-citationBruno, S., Marco, V. D., Iavarone, M. A., Roffi, L., Crosignani, A., Calvaruso, V., Aghemo, A., Cabibbo, G., Viganò, M., Boccaccio, V., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.034 · Cited by 123
Self-citationHung, C., Lee, C. ‐., Lu, S., Wang, J. ‐., Hu, T., Tung, H., Chen, C., Chen, W., & Changchien, C. ‐. (2006) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2005.00707.x · Cited by 115
Janjua, N. Z., Chong, M., Kuo, M. E., Woods, R. R., Wong, J., Yoshida, E. M., Sherman, M., Butt, Z. A., Samji, H., Cook, D. A., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.10.028 · Cited by 109
Jacobson, I. M., Lim, J. K., & Fried, M. W. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.03.018 · Cited by 82
Effect of HCV clearance with direct-acting antiviral agents on HCC
Llovet, J. M., & Villanueva, A. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.140 · Cited by 80
D’Ambrosio, R., Aghemo, A., Rumi, M. G., Primignani, M., Dell’Era, A., Lampertico, P., Donato, M. F., Nicola, S. D., Prati, G. M., de Franchis, R., et al. (2011) · Antiviral Therapy · doi:10.3851/imp1807 · Cited by 51
Velosa, J., Serejo, F., Marinho, R. T., Nunes, J., & Gloria, H. C. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1621-2 · Cited by 50
Is there sufficient evidence to recommend antiviral therapy in hepatitis C?
van der Meer, A. J., Wedemeyer, H. H., Feld, J. J., Hansen, B. E., Manns, M. P., Zeuzem, S., & Janssen, H. L. A. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.07.043 · Cited by 47
Waziry, R., Grebely, J., Amin, J., Alavi, M., Hajarizadeh, B., George, J., Matthews, G. V., Law, M. G., & Dore, G. J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.08.010 · Cited by 41
Hepatitis C treatment and liver cancer recurrence: cause for concern?
Debes, J. D., Janssen, H. L. A., & Boonstra, A. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30204-7 · Cited by 15
Cited by
Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
“However a residual risk of liver-related complications still persists after SVR, particularly HCC occurrence, and the role of non-invasive tools in stratifying this risk remains debated [91, 92].”
BackgroundSelf-citationEASL recommendations on treatment of hepatitis C: Final update of the series☆
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.018 · Cited by 1,252
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Kanwal, F., Kramer, J. R., Asch, S. M., Cao, Y., Li, L., & El‐Serag, H. B. (2020) · Hepatology · doi:10.1002/hep.30823 · Cited by 277
Intratumoural microbiota: a new frontier in cancer development and therapy
Cao, Y., Xia, H., Tan, X., Shi, C., Ma, Y., Meng, D., Zhou, M., Lv, Z., Wang, S., & Jin, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01693-0 · Cited by 253
Metadata
- Authors
- Calvaruso, V., Cabibbo, G., Cacciola, I., Petta, S., Madonia, S., Bellia, A., Tinè, F., Distefano, M., Licata, A., Giannitrapani, L., Prestileo, T., Mazzola, G., Di Rosolini, M. A., Larocca, L., Bertino, G., Digiacomo, A., Benanti, F., Guarneri, L., Averna, A., Iacobello, C., Magro, A., Scalisi, I., Cartabellotta, F., Savalli, F., Barbara, M., Davì, A., Russello, M., Scifo, G., Squadrito, G., Cammà, C., Raimondo, G., Craxì, A., Di Marco, V., Craxì, A., Di Marco, V., Cammà, C., Calvaruso, V., Petta, S., Cabbibbo, G., Colletti, P., Mazzola, G., Cascio, A., Montalto, G., Licata, A., Giannitrapani, L., Prestileo, T., Di Lorenzo, F., Sanfilippo, A., Ficalora, A., Madonia, S., Tinè, F., Malizia, G., Latteri, F., Maida, M., Cartabellotta, F., Vassallo, R., Cacciola, I., Caccamo, G., Maimone, S., Saitta, C., Squadrito, G., Raimondo, G., Mondello, L., Smedile, A., D’Andrea, S., Bertino, G., Ardiri, A. L., Frazzetto, E., Rigano, G., Montineri, A., Larocca, L. N., Cacopardo, B., Benanti, F., Russello, M., Benigno, R., Bellia, A., Iacobello, C., Davì, A., Di Rosolini, M. A., Digiacomo, A., Fuduli, G., Scifo, G., Distefano, M., Portelli, V., Savalli, F., Scalici, I., Gioia, G., Magro, A., Alaimo, G., Alinovi, M. R., Salvo, A., Averna, A., Lomonaco, F., Guarneri, L., Maffeo, F., Falzone, E., & Pulvirenti, F.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 155
- Issue
- 2
- Pages
- 411-421.e4
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2797952741
- Cited by
- 361
- References
- 34
- FWCI
- 30.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.